Protocol for an embedded randomised controlled trial of Early versus Late Stopping of Antibiotics in children with Febrile Neutropenia (ELSA-FN)
Details
Publication Year 2024,Volume 19,Issue #12,Page e0311523
Journal Title
PLoS One
Publication Type
Protocol
Abstract
In children with cancer, febrile neutropenia (FN) is one of the most common complications of treatment, a leading cause of unplanned and prolonged hospital admission and is the key driver of antibiotic exposure. Co-designed with key stakeholders, 'Early versus Late Stopping of Antibiotics in high-risk FN' (ELSA-FN) is a randomised controlled, non-inferiority trial that compares stopping antibiotics in clinically stable patients after 48 hours with the current standard of care, continuing antibiotics until absolute neutrophil recovery. As an Australian first, we will exploit the potential of electronic medical record (EMR) systems, embedding all key aspects of the trial including screening, consent, randomisation and data collection into standard clinical and EMR workflows. We aim to randomise 320 children with high-risk FN and prospectively collect data on safety, acceptability to clinicians and families, as well as several secondary outcomes related to antibiotic exposure. The findings will contribute to optimal antibiotic use in children with FN internationally and inform design and implementation of future EMR-embedded trials.
Publisher
PLOS
Keywords
Adolescent; Child; Child, Preschool; Female; Humans; Male; *Anti-Bacterial Agents/administration & dosage/therapeutic use/adverse effects; Australia; Electronic Health Records; *Febrile Neutropenia/drug therapy; Randomized Controlled Trials as Topic
Department(s)
Infectious Diseases
Open Access at Publisher's Site
https://doi.org/10.1371/journal.pone.0311523
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-01-07 03:38:10
Last Modified: 2025-01-07 03:42:55

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙